What Does RA Pharmaceuticals Do?

Total employees87
HeadquartersCambridge
Founded2008

RA Pharmaceuticals was a clinical-stage biopharmaceutical company committed to developing novel therapies for patients suffering from rare complement-mediated diseases. Its lead product candidate, Zilucoplan, a self-administered peptide inhibitor of complement component 5 (C5), was being developed for generalized myasthenia gravis (gMG), immune-mediated necrotizing myopathy (IMNM), and other tissue-based complement-mediated disorders. Founded in 2008 and headquartered in Cambridge, Massachusetts, RA Pharmaceuticals made significant advancements in the field before being acquired by UCB in April 2020 for approximately $2.1 billion (net of cash). This acquisition was aimed at bolstering UCB's portfolio in neurology and immunology, particularly in treating rare diseases.

Where Is RA Pharmaceuticals's Headquarters?

HQ Function

Served as the central hub for corporate operations, research and development (R&D) laboratories, clinical trial management, and administrative functions supporting the company's drug development pipeline.

Notable Features:

Strategically located in Kendall Square, a leading global biotech innovation hub, providing proximity to world-class research institutions, talent, and potential collaborators. The facility likely included modern laboratory and office spaces tailored for biopharmaceutical research.

Work Culture:

Characterized by a fast-paced, science-driven, and collaborative environment typical of clinical-stage biotechnology companies. There was likely a strong emphasis on innovation, scientific rigor, and a patient-focused mission.

HQ Significance:

The Cambridge headquarters was pivotal for RA Pharmaceuticals' progress, enabling the discovery and development of its complement C5 inhibitor pipeline, including Zilucoplan. Its location facilitated access to essential resources and talent in the competitive biotech landscape.

Values Reflected in HQ: The headquarters' location and setup likely reflected RA Pharmaceuticals' core values of innovation, scientific excellence, collaboration, and a dedication to addressing unmet medical needs in rare diseases.

Location:

Prior to its acquisition by UCB, RA Pharmaceuticals's global presence was primarily driven by its international clinical trial activities for Zilucoplan, which involved study sites across North America, Europe, and other key regions. While direct international office infrastructure was limited, the company collaborated with global clinical research organizations (CROs) and academic institutions to conduct its research and development programs worldwide. Its strategic focus was on advancing its pipeline through these global collaborations rather than establishing a widespread physical office network.

Street Address:

800 Technology Square

City:

Cambridge

State/Province:

Massachusetts

Country:

USA

Where Else Does RA Pharmaceuticals Operate Around the World?

No additional office locations available.

Buying Intent Signals for RA Pharmaceuticals

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading RA Pharmaceuticals? Meet the Executive Team

As of April 2025, RA Pharmaceuticals' leadership includes:

Douglas A. Treco, Ph.D. - President and Chief Executive Officer
David C. Lubner - Executive Vice President and Chief Financial Officer
Simon Read, Ph.D. - Chief Scientific Officer
Raphael Clynes, M.D., Ph.D. - Chief Medical Officer
John C. King - Chief Commercial Officer
Brian M. subgoal - General Counsel and Chief Compliance Officer

Who's Investing in RA Pharmaceuticals?

RA Pharmaceuticals has been backed by several prominent investors over the years, including:

New Enterprise Associates (NEA)
Novartis Venture Fund
Lightstone Ventures
RA Capital Management
Atlas Venture
Sofinnova Partners

What Leadership Changes Has RA Pharmaceuticals Seen Recently?

Hire2
Exits1

In the 12-18 months preceding its acquisition announcement in October 2019, RA Pharmaceuticals made strategic additions to its executive team, notably appointing a new Chief Financial Officer and a Chief Commercial Officer. This period also saw the departure of its previous CFO. Following the acquisition by UCB in April 2020, the RA Pharmaceuticals executive team was integrated into UCB or transitioned out.

Departures

Alice Tsang DeNoncourt, Alice Tsang DeNoncourt resigned as CFO. The role was filled on an interim basis before David C. Lubner's appointment in June 2019.

New Appointments:

David C. Lubner, David C. Lubner appointed as new EVP and CFO, bringing significant biopharma financial expertise.
John C. King, John C. King appointed as new CCO to spearhead commercial strategy.

What Technology (Tech Stack) Is Used byRA Pharmaceuticals?

Discover the tools RA Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

RA Pharmaceuticals Email Formats and Examples

Prior to its acquisition by UCB, RA Pharmaceuticals likely utilized standard corporate email address formats. While specific internal policies are not public, common patterns in the biopharmaceutical industry include combinations of first name, last name, and initials. Post-acquisition, official communications would transition to UCB's email systems.

A common email format at RA Pharmaceuticals was likely `[first_initial][last]@rapharma.com`.

Format

jdoe@rapharma.com

Example

75%

Success rate

What's the Latest News About RA Pharmaceuticals?

UCB Press Release • October 10, 2019

UCB Announces Agreement to Acquire RA Pharmaceuticals

UCB and RA Pharmaceuticals announced a definitive agreement under which UCB would acquire RA Pharma for $48 per share in cash, equating to an approximate enterprise value of $2.1 billion (net of cash). The acquisition aimed to enhance UCB's leadership in treating myasthenia gravis and other rare diseases by adding RA Pharma's lead candidate, Zilucoplan, to its portfolio....more

Business Wire (RA Pharma Press Release) • December 4, 2018

RA Pharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of Zilucoplan in Generalized Myasthenia Gravis

RA Pharmaceuticals reported positive topline results from its Phase 2 clinical trial evaluating Zilucoplan in patients with generalized myasthenia gravis (gMG). The trial successfully met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in disease severity scores compared to placebo....more

UCB Press Release • April 2, 2020

UCB Completes Acquisition of Ra Pharmaceuticals

UCB announced the successful completion of its acquisition of Ra Pharmaceuticals, Inc. This transaction further strengthened UCB's pipeline with Zilucoplan, a promising therapy for severe chronic rare diseases....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including RA Pharmaceuticals, are just a search away.